Observational studyMedicine2026
Echocardiography for the evaluation of the relationship between lower abdominal aorta watershed and renal function injury during veno-arterial extracorporeal membrane oxygenation: A retrospective study.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This investigation aims to elucidate the impact of echocardiography in assessing the association between the watershed region of the lower abdominal aorta and renal function impairment during veno-arterial extracorporeal membrane oxygenation (VA-ECMO) therapy. In this retrospective cohort study, patients who underwent VA-ECMO treatment for left heart failure at one hospital from March 2014 to November 2021 were included. Based on the position of the watershed in the lower abdominal aorta during ECMO therapy, according to echocardiography, subjects were categorized into 2 cohorts: the upper watershed group and the lower watershed group. The primary endpoint was an elevation in serum creatinine levels exceeding 133 μmol/L within 24 hours following the discontinuation of VA-ECMO. The cohort comprised 657 participants, with 437 allocated to the lower watershed group and 220 to the upper watershed group. No significant disparities were observed between the groups in terms of age (P = .078), gender (P = .638), and the underlying cause for VA-ECMO deployment (P = .865). The likelihood of successful weaning from VA-ECMO was notably higher in the lower watershed group compared to the upper watershed group (97.0% vs 88.2%, P < .001). Conversely, the upper watershed group exhibited elevated mortality (8.2% vs 2.3%, P < .001) and renal failure (16.4% vs 4.1%, P < .001) rates. A significant difference in serum creatinine levels was recorded between the groups (β = 64.176, P < .001), with the upper watershed group demonstrating a higher association with serum creatinine levels exceeding 133 μmol/L within 24 hours post-VA-ECMO weaning (compared to the lower group, odds ratio = 15.206, 95% confidence interval: 9.791-23.616, P < .001). The echocardiographically determined position of the watershed above the lower abdominal aorta was found to be independently associated with an increased risk of serum creatinine levels exceeding 133 μmol/L within 24 hours after weaning from VA-ECMO. Additional multicenter, prospective validation studies are necessary to determine the exact causality between watershed position and ECMO weaning outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.